{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:20:26Z","timestamp":1789518026320,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1016\/j.diabres.2005.06.010","type":"journal-article","created":{"date-parts":[[2005,8,20]],"date-time":"2005-08-20T11:18:48Z","timestamp":1124536728000},"page":"210-219","source":"Crossref","is-referenced-by-count":53,"title":["Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension"],"prefix":"10.1016","volume":"71","author":[{"given":"Ahmet M.","family":"Sengul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y\u00fcksel","family":"Altuntas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ak\u0131n","family":"K\u00fcrkl\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levent","family":"Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2005.06.010_bib1","series-title":"The Kidney","first-page":"1731","article-title":"Diabetic nephropathy","author":"Parving","year":"2000"},{"issue":"Suppl. 1","key":"10.1016\/j.diabres.2005.06.010_bib2","first-page":"S85","volume":"25","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2005.06.010_bib3","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0300-595X(86)80074-3","article-title":"Clinical diabetic nephropathy: natural history and complications","volume":"15","author":"Grenfell","year":"1986","journal-title":"Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.diabres.2005.06.010_bib4","first-page":"S7","article-title":"Microalbuminuria: a common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes","volume":"21","author":"Donnelly","year":"2003","journal-title":"J. Hypertens."},{"key":"10.1016\/j.diabres.2005.06.010_bib5","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1001\/archinte.157.13.1413","article-title":"The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus","volume":"157","author":"Dinneen","year":"1997","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.diabres.2005.06.010_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.1365-2796.2003.01157.x","article-title":"Microalbuminuria and hypertension, with focus on type 1 and type 2 diabetes","volume":"254","author":"Mogensen","year":"2003","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.diabres.2005.06.010_bib7","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1592\/phco.23.7.909.32726","article-title":"Angiotensin-converting enzyme inhibitors and type 2 diabetic nephropathy: a meta-analysis","volume":"23","author":"Hamilton","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.diabres.2005.06.010_bib8","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0272-6386(00)70018-7","article-title":"Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials","volume":"35","author":"Kshirsagar","year":"2000","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.diabres.2005.06.010_bib9","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N. Engl. J. Med."},{"issue":"Suppl.","key":"10.1016\/j.diabres.2005.06.010_bib10","first-page":"S150","article-title":"Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria","volume":"45","author":"Lebovitz","year":"1994","journal-title":"Kidney Int."},{"issue":"Suppl. 2","key":"10.1016\/j.diabres.2005.06.010_bib11","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1097\/01.ASN.0000070142.14843.8E","article-title":"Prevention of hypertension and its complications: theoretical basis and guidelines for treatment","volume":"14","author":"Flack","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.diabres.2005.06.010_bib12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11892-002-0091-5","article-title":"Role of ACE inhibitors in treating hypertensive diabetic patients","volume":"2","author":"Kirpichnikov","year":"2002","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.diabres.2005.06.010_bib13","first-page":"428","article-title":"Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency","volume":"15","author":"Pisoni","year":"2002","journal-title":"J. Nephrol."},{"key":"10.1016\/j.diabres.2005.06.010_bib14","first-page":"482","article-title":"Angiotensin-converting enzyme inhibition-induced changes in hippurate renography and renal function in renovascular hypertension","volume":"37","author":"Visscher","year":"1996","journal-title":"J. Nucl. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.diabres.2005.06.010_bib15","first-page":"S3","article-title":"Angiotensin converting enzyme inhibitors and vascular protection in hypertension","volume":"34","author":"Ruschitzka","year":"1999","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.diabres.2005.06.010_bib16","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2165\/00003495-200161070-00004","article-title":"Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension","volume":"61","author":"Ruzicka","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.diabres.2005.06.010_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1517\/14740338.3.1.9","article-title":"Can dual blockade of the renin-angiotensin system reduce progression of kidney disease beyond monotherapy?","volume":"3","author":"Brewster","year":"2004","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.diabres.2005.06.010_bib18","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/00004872-199208000-00015","article-title":"Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response?","volume":"10","author":"van den Meiracker","year":"1992","journal-title":"J. Hypertens."},{"key":"10.1016\/j.diabres.2005.06.010_bib19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/sj.jhh.1001022","article-title":"Chymase-dependent angiotensin II formation in human blood vessels","volume":"14","author":"Chester","year":"2000","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.diabres.2005.06.010_bib20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/dmrr.363","article-title":"Treatment of diabetic nephropathy in its early stages","volume":"19","author":"Deferrari","year":"2003","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.diabres.2005.06.010_bib21","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diabres.2005.06.010_bib22","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s11906-003-0088-8","article-title":"How high should an ACE inhibitor or an angiotensin receptor blocker be dosed in patients with diabetic nephropathy?","volume":"5","author":"Weinberg","year":"2003","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.diabres.2005.06.010_bib23","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/152091502760098456","article-title":"Combination antihypertensive therapy in the treatment of diabetic nephropathy","volume":"4","author":"Boner","year":"2002","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.diabres.2005.06.010_bib24","first-page":"206","article-title":"Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension","volume":"15","author":"Neutel","year":"1998","journal-title":"Adv. Ther."},{"key":"10.1016\/j.diabres.2005.06.010_bib25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.amjhyper.2004.02.016","article-title":"Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period","volume":"17","author":"White","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.diabres.2005.06.010_bib26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00126097-200408000-00005","article-title":"Sustained antihypertensive activity of telmisartan compared with valsartan","volume":"9","author":"Lacourci\u00e8re","year":"2004","journal-title":"Blood Press. Monit."},{"key":"10.1016\/j.diabres.2005.06.010_bib27","series-title":"Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation","year":"1999"},{"key":"10.1016\/j.diabres.2005.06.010_bib28","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1093\/clinchem\/29.12.2026","article-title":"Quantification of high-density-lipoprotein cholesterol by precipitation with phosphotungstic acid\/MgCl2","volume":"29","author":"Assmann","year":"1982","journal-title":"Clin. Chem."},{"key":"10.1016\/j.diabres.2005.06.010_bib29","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin. Chem."},{"key":"10.1016\/j.diabres.2005.06.010_bib30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004872-200018010-00013","article-title":"Safety of the combination of valsartan and benazepril in patients with chronic renal disease","volume":"18","author":"Ruilope","year":"2000","journal-title":"J. Hypertens."},{"key":"10.1016\/j.diabres.2005.06.010_bib31","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","article-title":"Randomized controlled trial of dual blockade of renin-angiotensin system with hypertension, microalbuminuria and non-insulin-dependent diabetes: the candesartan lisinopril microalbuminuria (CALM) study","volume":"321","author":"Mogensen","year":"2000","journal-title":"Br. Med. J."},{"key":"10.1016\/j.diabres.2005.06.010_bib32","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1046\/j.1523-1755.2003.00940.x","article-title":"Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy","volume":"63","author":"Jacobsen","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.diabres.2005.06.010_bib33","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.2337\/diacare.26.8.2268","article-title":"Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial","volume":"26","author":"Rossing","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2005.06.010_bib34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1023\/A:1023244829975","article-title":"Diabetic nephropathy\u2014pathophysiology and management","volume":"34","author":"Shumway","year":"2002","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.diabres.2005.06.010_bib35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0270-9295(03)00061-5","article-title":"Outcome studies in diabetic nephropathy","volume":"23","author":"Mohanram","year":"2003","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.diabres.2005.06.010_bib36","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.2337\/diabetes.46.10.1612","article-title":"Role of angiotensin II and bradykinin in experimental diabetic nephropathy","volume":"46","author":"Allen","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2005.06.010_bib37","first-page":"176","article-title":"Bradykinin-induced bronchoconstriction. Mode of action","volume":"135","author":"Fuller","year":"1987","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.diabres.2005.06.010_bib38","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJM199606203342507","article-title":"Angiotensin receptors and their antagonists","volume":"334","author":"Goodfriend","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diabres.2005.06.010_bib39","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diabres.2005.06.010_bib40","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s001250050983","article-title":"Renoprotection in diabetes: genetic and non-genetic risk factors and treatment","volume":"41","author":"Parving","year":"1998","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2005.06.010_bib41","doi-asserted-by":"crossref","first-page":"R971","DOI":"10.1152\/ajpregu.00262.2003","article-title":"Effects of different angiotensins during acute, double-blockade of the renin system in conscious dogs","volume":"285","author":"Wamberg","year":"2003","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.diabres.2005.06.010_bib42","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1053\/ajkd.2002.29909","article-title":"Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels","volume":"39","author":"Komine","year":"2002","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.diabres.2005.06.010_bib43","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1097\/00005344-198211000-00014","article-title":"Antihypertensive therapy with MK 421: angiotensin II\u2013renin relationships to evaluate efficacy of converting enzyme blockade","volume":"4","author":"Biollaz","year":"1982","journal-title":"J. Cardiovasc. Pharmacol."}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822705002792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822705002792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T04:32:58Z","timestamp":1586406778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822705002792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["S0168822705002792"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2005.06.010","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2006,2]]}}}